Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia

Fig. 1

Characterization of the tau294–305 epitope to hepatitis B core immunodominant region (T294-HBc) virus-like particle (VLP) vaccine. a Schematic representation of the genetic fusion constructs of T294-HBc. The tau294–305 epitope was inserted in the major immunodominant region (MIR) between amino acids 78 and 79 with a GSG linker on each side of the epitope. b After preparation, T294-HBc VLPs were subjected to 15% SDS-PAGE to detect the purity of T294-HBc. c The samples were then applied to copper grids, negatively stained, and imaged by TEM (Hitachi, Tokyo, Japan) at 80 kV and × 60,000 magnification. d The size distribution of VLPs determined by TEM was measured using Nano Measurer 1.2 (n = 100). Scale bar is 200 nm

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193